This is an aggregated industry headline. Read the full story at BioPharma Dive →
Novo setback casts doubt on a new way to treat heart disease
Ziltivekimab's failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.
By BioPharma Dive
· Jul 31, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Amylyx's patient education website aims to empower patients to navigate post-bariatric hypoglycemia (PBH), a r…
The WeekFierceBiotech ↗
A phase 3 trial of Novo Nordisk's ziltivekimab has missed its primary endpoint, denting the prospects of a mol…
The WeekBriefing
FiercePharma’s “The Top Line” highlighted three pressure points this week: M&A in psychedelics, peptide re…